Hypokalemia, Its Contributing Factors and Renal Outcomes in Patients with Chronic Kidney Disease

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
Wang, Hsiao-Han, Chi-Chih Hung, Daw-Yang Hwang, Mei-Chuan Kuo, Yi-Wen Chiu, Jer-Ming Chang, Jer-Chia Tsai, Shang-Jyh Hwang, Julian L. Seifter, and Hung-Chun Chen. 2013. “Hypokalemia, Its Contributing Factors and Renal Outcomes in Patients with Chronic Kidney Disease.” PLoS ONE 8 (7): e67140. doi:10.1371/journal.pone.0067140. http://dx.doi.org/10.1371/journal.pone.0067140.

Published Version
doi:10.1371/journal.pone.0067140

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11717664

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Hypokalemia, Its Contributing Factors and Renal Outcomes in Patients with Chronic Kidney Disease

Hsiao-Han Wang1,6*, Chi-Chih Hung1,4*, Daw-Yang Hwang1, Mei-Chuan Kuo1,3, Yi-Wen Chiu1,3, Jer-Ming Chang1,2,3, Jer-Chia Tsai1,4, Shang-Jyh Hwang1,3, Julian L. Seifter5, Hung-Chun Chen1,3*

1 Division of Nephrology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, 2 Department of Internal Medicine, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, 3 Faculty of Renal Care, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 4 Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 5 Renal Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, 6 Department of Dermatology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

Abstract

Background: In the chronic kidney disease (CKD) population, the impact of serum potassium (sK) on renal outcomes has been controversial. Moreover, the reasons for the potential prognostic value of hypokalemia have not been elucidated.

Design, Participants & Measurements: 2500 participants with CKD stage 1–4 in the Integrated CKD care program Kaohsiung for delaying Dialysis (ICKD) prospective observational study were analyzed and followed up for 2.7 years. Generalized additive model was fitted to determine the cutpoints and the U-shape association between sK and end-stage renal disease (ESRD). sK was classified into five groups with the cutpoints of 3.5, 4, 4.5 and 5 mEq/L. Cox proportional hazard regression models predicting the outcomes were used.

Results: The mean age was 62.4 years, mean sK level was 4.2 ± 0.5 mEq/L and average eGFR was 40.6 ml/min per 1.73 m². Female vs male, diuretic use vs. non-use, hypertension, higher eGFR, bicarbonate, CRP and hemoglobin levels significantly correlated with hypokalemia. In patients with lower sK, nephrotic range proteinuria, and hypoalbuminemia were more prevalent but the use of RAS (renin-angiotensin system) inhibitors was less frequent. Hypokalemia was significantly associated with ESRD with hazard ratios (HRs) of 1.82 (95% CI, 1.03–3.22) in sK < 3.5 mEq/L and 1.67 (95% CI, 1.19–2.35) in sK = 3.5–4 mEq/L, respectively, compared with sK = 4.5–5 mEq/L. Hyperkalemia defined as sK > 5 mEq/L conferred 1.6-fold (95% CI, 1.09–2.34) increased risk of ESRD compared with sK = 4.5–5 mEq/L. Hypokalemia was also associated with rapid decline of renal function defined as eGFR slope below 20% of the distribution range.

Conclusion: In conclusion, both hypokalemia and hyperkalemia are associated with increased risk of ESRD in CKD population. Hypokalemia is related to increased use of diuretics, decreased use of RAS blockade and malnutrition, all of which may impose additive deleterious effects on renal outcomes.

Introduction

The kidney plays a major role in potassium homeostasis by renal mechanisms that transport and regulate potassium secretion, reabsorption and excretion [1]. Hyperkalemia is a common electrolyte disturbance in patients with chronic kidney disease (CKD) [2]. As eGFR decreases from above 60 to below 20 ml/min/1.73 m², the prevalence of hyperkalemia increases from 2 to 42% [3]. In CKD individuals, a few studies suggested weak links between hyperkalemia and ESRD [4,5].

Chronic hypokalemia, on the other hand, has been reported to enhance renal cytogenesis and may lead to interstitial scarring and renal insufficiency [6,7]. Recently, in CKD patients comorbid with and without cardiovascular diseases, the associations between hypokalemia and death as well as ESRD have been proposed [4,5,8]. One paper demonstrated hypokalemia was associated with ESRD but this effect was attenuated after adjusting nutritional indices in patients with CKD stage 3 to 5 [4]. Another study suggested hypokalemia was associated with renal progression but the association with hard renal outcome, such as reaching ESRD was unclear [5].

Recent studies have reported common predispositions such as diabetes, high dietary potassium and renin-angiotensin-aldosterone system blockers use for the development of hyperkalemia in patients with impaired renal functions [9–12]. Kaliuretic diuretics such as furosemide and thiazides are common causes of hypokalemia [13,14]. Diarrhea, vomiting, hyperaldosteronism, magnesium deficiency and potassium redistribution induced by...
insulin, alkalosis and/or β-adrenergic activation, are all possible prerequisites for hypokalemia [15]. However, studies on hypokalemia and aforementioned associated factors were done mostly in general population. Moreover, the possible complex interplay between hypokalemia, its associating factors and renal outcomes has not been investigated.

In the CKD population, whether sK level is associated with greater risks of renal outcomes has not been clearly defined. Moreover, the verification of the reasons for the potential prognostic value of hypokalemia remains to be elucidated. Thus, we investigated the contributing factors of hypokalemia and whether hyperkalemia or hypokalemia is a risk factor for adverse renal outcomes in patients with CKD stage 1 to 4.

### Methods

#### Participants and Measurement

Integrated CKD care program Kaohsiung for Delaying Dialysis (ICKD) study was designed as a prospective cohort to investigate the impact of integrated CKD care program on clinical outcomes from a diverse group of CKD stage 1–5 patients. The included population was CKD patients not on renal replacement therapy. The exclusion criterion was acute kidney injury defined as more than 50% decrease in eGFR in three months. The study recruited patients from the nephrology out-patient departments of two hospitals in southern Taiwan. Between November 11, 2002 and May 31, 2009, 3749 patients received integrated CKD care program and were followed up until July 31, 2010. 90 patients were lost for follow-ups in less than 3 months and 1159 stage 5 CKD patients were excluded. Total 2500 subjects with CKD stage 1 to 4 were analyzed. The study protocol was approved by the institutional review board of the Kaohsiung Medical University Hospital (KMUH-IRB-990198). Informed consents have been obtained in written form from patients and all clinical investigation was conducted according to the principles expressed in the Declaration of Helsinki. The patients gave consent for the publication of the clinical details.

At the baseline visit, socio-demographic characteristics, medical history, lifestyle behaviors and current medications were recorded. The medical history was confirmed by doctors’ chart-review. Diabetes mellitus (DM) and hypertension were defined by clinical diagnosis. Cardiovascular disease (CVD) was defined as clinical diagnosis of heart failure, acute or chronic ischemic heart disease, or cerebrovascular disease. Body Mass Index (BMI) was calculated from the baseline enrolled measurement using the formula: weight in kilograms/height in meters². Mean blood pressure (MBP) was calculated by the averages of systolic and diastolic BP measured 3 months before and after the enrollment using the formula: 2/3 average systolic BP + 1/3 average diastolic BP.

Biochemistry measurements were done on screening visit, baseline visit and then every 3 months as the protocol. The laboratory data from 3 months before baseline visit to 3 months after baseline visit were averaged and analyzed. Six-month averaged sK was used for analysis and was classified into five groups as: sK <3.5; K = 3.5–4; K = 4–4.5; K = 4.5–5 and K >5 mEq/L. The cutpoints were defined by generalized additive regression. Serum creatinine, albumin, cholesterol, C-reactive protein (CRP), potassium and phosphate levels were determined by means of the ‘Toshiba TBA C16000 chemistry analyzer. Serum hemoglobin was determined by means of the Sysmex XE-2100 automated hematology analyzer. HbA1C was measured by Primus CLC 385 automated analyzer. Venous blood bicarbonate was measured by AVL Omni 3 blood gas analyzer.

#### Quantification of Renal Function and Progression

Kidney function was quantified by using the estimated glomerular filtration rate (eGFR) derived from the simplified Modification of Diet in Renal Disease (MDRD) Study equation. The equation was eGFR ml/min/1.73 m² = 186 × Serum creatinine (µmol/L)¹.¹⁵⁴ × Age⁻⁰.⁷⁹⁰³ × 0.⁷⁴² (if female) × 1.²¹² (if black patient). The average eGFR slope (ml/min/1.73 m²/yr) for each patient was calculated by linear regression with varying-intercept and varying-slope without co-variates for estimation of the annual change of eGFR.

#### Outcomes

Renal outcomes were assessed: end stage renal disease (ESRD) and rapid renal progression. ESRD was defined as the initiation of hemodialysis, peritoneal dialysis or renal transplantation. The initiation of renal replacement therapy was discovered by review of charts or catastrophic cards. Rapid renal progression was defined as an eGFR slope <−6.88 ml/min/1.73 m²/yr which was the 20th percentile. Other cut-off values were also applied in sensitivity tests. The timing for ESRD was according to the regulation of Bureau of the National Health Insurance of Taiwan regarding the laboratory data, nutritional status, uremic status and serum creatinine (>6 mg/dL). ESRD was ascertained by reviewing charts and by matching with the database from Taiwan Society of Nephrology.

#### Statistical Analysis

Statistic results of baseline characteristics of all subjects were expressed as percentages for categorical variables, mean ± standard deviation (SD) for continuous variables with approximately-normal distribution, and median and interquartile range for continuous variables with skewed distribution.

We conducted both linear regression and generalized additive models (GAM) to investigate the variables associated with sK. GAM were fitted to detect nonlinear effects of continuous covariates (VGAM function of the VGAM package) [16,17] for sK because GAM were developed for smoothing the effects of covariates in generalized linear models. The selection of variables was based on previous models and also the nutritional and medication variables that we hypothesized.

Cox proportional hazards models were used to evaluate association of variables with time to ESRD. Covariates included in these models were age, gender, DM, CVD, eGFR, Urine protein by dipstick, Angiotensin-converting enzyme inhibitor (ACEI), Angiotensin II receptor blocker (ARB), diuretics, MBP, BMI, HbA1c, log-transformed cholesterol, log-transformed CRP, phosphate, hemoglobin and albumin. Generalized additive models with restricted cubic regression splines were used to explore the functional form of the relationship between sK and ESRD. The knots for sK were at 4.03 and 5.11 mEq/L and we thus divided sK accordingly in the tables. Binary logistic regression analysis was used to assess the relationship between sK and rapid renal progression. Covariates included into these models were the same as those in Cox regression.

Also, the statistical tools for regression diagnostics such as verification of proportional hazards assumption, residual analysis, detection of influential cases, and check for multicolinearity were applied to discover model or data problems. Statistical analysis was performed using the R 2.15.2 software (R Foundation for Statistical Computing, Vienna, Austria) and Statistical Package for Social Sciences version 18.0 for Windows (SPSS Inc., Chicago, IL).
Results

Baseline Characteristics of CKD Patients Divided by Serum Potassium Quintiles

A total of 2500 participants in CKD stage 1–4 were analyzed during a median 2.7-year of follow-up. Figure 1 displayed the distribution of five sK groups by CKD stage 1–4. There was still 5.6% of participants with sK <3.5 mEq/L in those with CKD stage 4, while there was less than 1% of patients with sK >5 mEq/L in those with CKD stage 1. The majority of the participants were male (64%), had hypertension (61.3%) with a mean age of 62.4±14.5 years, mean sK of 4.2±0.5 mEq/L and mean eGFR of 40.6±23.3 ml/min/1.73 m² (Table 1). Patients with lower sK were more likely to have hypertension, higher eGFR, higher serum hemoglobin, cholesterol and bicarbonate levels, whereas they were less likely to have a history of diabetes, to have higher HbA1c and phosphate levels, in comparison with those with higher sK. Figure 2 further demonstrated the relationship between sK and other important predictive covariates. There were higher proportions of patients presenting with hypoalbuminemia (<3.5 mg/dL) and lower BMI (20 kg/m²) in the groups with sK <3.5 and >5mEq/L (Figure 2A).

In total participants, ESRD rate was 43 per 1000 person-years (Table 1). There was a trend of greater crude rates of ESRD and steeper decline in eGFR in groups with higher sK. There were no significant univariate linear relationships between sK groups and rapid renal progression and increment of proteinuria respectively. However, greater increase of proteinuria and higher proportion of participants with rapid renal progression were observed in the groups with sK <3.5 mEq/L and sK >5 mEq/L with p for Chi-Square as p = 0.009 and p<0.001 respectively.

The percentages of patients receiving ACEI, ARB, oral hypoglycemic agents and insulin were higher in those with more elevated sK (Table 2). The proportions of other medication use such as furosemide, thiazide, phosphate binder and β-blocker did not show significant trends among groups. Despite similar MBP across five groups of sK, the use of anti-hypertensive medication was less frequent while the use of diuretics was more prevalent as sK decreased (Figure 2B). The prevalence of nephrotic range proteinuria was the highest in the groups with sK <3.5 and >5 mEq/L, but the use of RAS inhibitors was the least in sK <3.5 mEq/L (Figure 2C).

All the univariate significant and non-significant but relevant covariates were tested in multivariate linear regression for sK (Table 3). Non-linear effects of continuous variables were tested by generalized additive models (Table S1 and Figure S1). sK was negatively correlated with eGFR, MBP, bicarbonate, CRP and hemoglobin and positively correlated with HbA1c and albumin. The use of ACEI, ARB, and insulin vs those non-users were associated with higher sK. Female vs. male and diuretics users vs. non-users were associated with lower sK (Table 3 and Table S1).

Potassium and Renal Replacement Therapy

There were 299 patients (12%) reaching ESRD during a median 2.7-year of follow-up. To explore the non-linear association of sK and ESRD, we fitted a generalized additive model with a restricted cubic spline regression (Figure 3). The result revealed a U-shaped association, with increased risk of ESRD when sK <4.03 mEq/L and sK >5.11 mEq/L. Consistent with these associations, when compared to sK = 4.5–5mEq/L, both sK <3.5 mEq/L and sK = 3.5–4 mEq/L were significantly associated with 82% (HR 1.82; CI 95% 1.03–3.22; p = 0.041) and 67% (HR 1.67; CI 95% 1.19–2.35; p = 0.003) excess risk of ESRD, respectively in fully-adjusted Cox regression (Table 4). sK >5mEq/L was also associated with increased risk of becoming ESRD with HR of 1.60 (CI 95% 1.09–2.34).

Other risk factors for ESRD revealed in the multivariate Cox regression analysis included diabetes, decreased eGFR, diuretic use, higher MBP, proteinuria (by dipstick or by urine protein-to-creatinine ratio (UPCR)), hyperphosphatemia, higher HbA1c, lower BMI, anemia and hypoalbuminemia (Table 4). We also tested the proportional hazard assumption and linearity assumption. The results were shown in Supplementary Table 2. Three variables including gender, albumin and bicarbonate were against proportional hazard assumption and were treated by stratification. Four variables including serum potassium, BMI, mean blood pressure and C-reactive protein had non-linear relationships with ESRD (Table S2 and Figure S2). An alternative model with UPCR showed similar results (data not shown).

Subgroup Analysis for Hypokalemia and Renal Replacement Therapy

The association between the sK <3.5mEq/L and ESRD was significant in patients with ARB use (HR 3.14; 1.36–7.24; p<0.001), but not in those without (HR 1.32; 0.58–2.97; p = 0.508; p for interaction, 0.041). The other pre-specified subgroups did not show significant interaction.

Potassium and Rapid Renal Progression

The median eGFR slope was −1.8 ml/min/1.73 m²/yr. There were 492 participants (20%) experiencing eGFR slope less than −6.88 ml/min/1.73 m²/yr. Serum K lower than 3.5 mEq/L was significantly associated with faster yearly decline in eGFR with odds ratio (OR) of 1.69 (CI 95% 1.06–2.70; p = 0.027) compared with sK = 4.5–5 mEq/L after full adjustment (Table 4). On the other hand, sK >5mEq/L didn’t show significant association with rapid progression of renal function. Additional risk factors for rapid renal progression included diabetes, higher MBP, less ARB use, proteinuria, hyperphosphatemia, higher HbA1c, anemia and hypoalbuminemia.

Discussion

In our cohort, we examined the associations between sK, its associating factors and renal outcomes in 2500 patients with CKD stage 1–4. We demonstrated that diuretic use vs. non-use, hypertension, higher bicarbonate, hemoglobin and CRP levels significantly correlated with hypokalemia. The use of ACEI, ARB,
### Table 1. Baseline Demographic and Clinical Characteristics

| Variable                      | All (n = 2500) | sK < 3.5 mEq/L (n = 134) | sK = 3.5–4 mEq/L (n = 683) | sK = 4–4.5 mEq/L (n = 974) | sK = 4.5–5 mEq/L (n = 474) |
|-------------------------------|----------------|--------------------------|-----------------------------|-----------------------------|-----------------------------|
| Age (years)                   | 62.4 ± 14.5    | 61.3 ± 14.9              | 62.7 ± 14.3                 | 63.7 ± 14.3                 | 63.8 ± 14.7                 |
| Gender (female %)             | 58.6 (583)     | 55.0 (75)                | 60.2 (409)                  | 58.3 (281)                  | 60.6 (86)                   |
| Hypertension (%)              | 89.9 (957)     | 87.5 (67)                | 91.6 (586)                  | 92.3 (434)                  | 93.4 (106)                  |
| Diabetes mellitus (%)         | 15.3 (161)     | 14.3 (10)                | 16.2 (96)                   | 15.9 (81)                   | 16.9 (35)                   |
| Cardiovascular disease (%)    | 54.6 (564)     | 53.2 (7)                 | 58.3 (360)                  | 57.2 (262)                  | 59.4 (94)                   |
| BMI (kg/m²)                   | 25.1 ± 4.0     | 25.0 ± 4.0               | 25.2 ± 4.1                  | 25.3 ± 4.1                  | 25.4 ± 4.5                  |
| Renal Function Status         |                |                          |                             |                             |                             |
| eGFR (mL/min/1.73 m²)         | 99.4 ± 13.4    | 99.5 ± 13.2              | 99.6 ± 13.5                 | 99.6 ± 13.5                 | 99.6 ± 13.8                 |
| Proteinuria by dipstick (%)   |                |                          |                             |                             |                             |
| none                          |                |                          |                             |                             |                             |
| CrP (mg/L)                    |                |                          |                             |                             |                             |
| Total cholesterol (mg/dL)     | 201.4 ± 56.2   | 202.5 ± 62.9             | 204.5 ± 62.3                | 206.5 ± 62.2                | 208.5 ± 62.2                |
| HbA1c (%)                     |                |                          |                             |                             |                             |
| CRP (mg/L)                    |                |                          |                             |                             |                             |
| UPCR (mg/g)                   |                |                          |                             |                             |                             |
| eGFR slope (mL/min/1.73 m²/yr)|                |                          |                             |                             |                             |
| eGFR increment                |                |                          |                             |                             |                             |
| Rapid renal progression*      |                |                          |                             |                             |                             |
| Proteinuria increment #       |                |                          |                             |                             |                             |
| Primary endpoints             |                |                          |                             |                             |                             |
| Rate per 1000 person-Years    |                |                          |                             |                             |                             |

Data expressed as mean ± standard deviation, median (interquartile range) or percentage. BMI, body mass index; MBP, mean blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; CrP, C-reactive protein; HbA1c, glycated hemoglobin; UPCR, Urine protein-to-creatinine ratio; ESRD, End Stage Renal Disease.

*Comparisons are made by ANOVA or the chi-square test.

**eGFR slope less than 26.88 mL/min/1.73 m²/yr (%).**

*Urine protein-to-creatinine (mg/g).*

doi:10.1371/journal.pone.0067140.t001
Figure 2. The Relationships between Serum Potassium and Other Predictive Covariates. Figure 2A. Percentages of malnutrition indices including serum albumin lower than 3.5 mg/dL and body mass index (BMI) less than 20 kg/m² across potassium groups. Figure 2B. Proportions of diuretics use (Thiazide and/or Furosemide use), anti-hypertensive (anti-HTN) medication and mean blood pressure (MBP) across potassium groups. Figure 2C. Proportions of ACEI, ARB and proteinuria with nephrotic range across potassium groups. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; UPCR, Urine protein-to-creatinine ratio. P-values were generated by chi-square tests.

doi:10.1371/journal.pone.0067140.g002

Table 2. Use of Medications.

| Medication Type | All (n = 2500) | ≤3.5 mEq/L (n = 194) | >3.5–4.5 mEq/L (n = 683) | >4.5–5 mEq/L (n = 974) | >5 mEq/L (n = 474) |
|-----------------|---------------|----------------------|--------------------------|-----------------------|-------------------|
| ACEI (%)        | 726 (29.0%)   | 43 (22.2%)           | 186 (27.2%)              | 298 (30.6%)           | 146 (30.8%)       |
| ARB (%)         | 1004 (40.2%)  | 54 (27.8%)           | 263 (38.5%)              | 388 (39.8%)           | 222 (46.8%)       |
| Furosemide (%)  | 313 (12.5%)   | 29 (14.9%)           | 90 (13.2%)               | 120 (12.3%)           | 52 (11.0%)        |
| Thiazide (%)    | 237 (9.5%)    | 24 (12.4%)           | 72 (10.5%)               | 103 (10.6%)           | 29 (6.1%)         |
| Oral hypoglycemic agents (%) | 725 (29.0%) | 42 (21.6%) | 217 (31.3%) | 180 (18.3%) | 18 (3.8%) |
| Insulin (%)     | 133 (6.1%)    | 7 (3.6%)             | 17 (2.5%)                | 61 (6.3%)             | 18 (3.8%)         |
| Phosphate binders (%) | 310 (12.4%) | 16 (8.2%) | 92 (13.5%) | 50 (10.5%) | 18 (3.8%) |
| β-blocker (%)   | 571 (22.8%)   | 43 (22.2%)           | 169 (24.7%)              | 210 (21.6%)           | 118 (24.9%)       |

Data expressed as mean ± standard deviation, median (interquartile range) or percentage.

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.

Table 2. Use of Medications.

| Medication Type | All (n = 2500) | ≤3.5 mEq/L (n = 194) | >3.5–4.5 mEq/L (n = 683) | >4.5–5 mEq/L (n = 974) | >5 mEq/L (n = 474) |
|-----------------|---------------|----------------------|--------------------------|-----------------------|-------------------|
| ACEI (%)        | 726 (29.0%)   | 43 (22.2%)           | 186 (27.2%)              | 298 (30.6%)           | 146 (30.8%)       |
| ARB (%)         | 1004 (40.2%)  | 54 (27.8%)           | 263 (38.5%)              | 388 (39.8%)           | 222 (46.8%)       |
| Furosemide (%)  | 313 (12.5%)   | 29 (14.9%)           | 90 (13.2%)               | 120 (12.3%)           | 52 (11.0%)        |
| Thiazide (%)    | 237 (9.5%)    | 24 (12.4%)           | 72 (10.5%)               | 103 (10.6%)           | 29 (6.1%)         |
| Oral hypoglycemic agents (%) | 725 (29.0%) | 42 (21.6%) | 217 (31.3%) | 180 (18.3%) | 18 (3.8%) |
| Insulin (%)     | 133 (6.1%)    | 7 (3.6%)             | 17 (2.5%)                | 61 (6.3%)             | 18 (3.8%)         |
| Phosphate binders (%) | 310 (12.4%) | 16 (8.2%) | 92 (13.5%) | 50 (10.5%) | 18 (3.8%) |
| β-blocker (%)   | 571 (22.8%)   | 43 (22.2%)           | 169 (24.7%)              | 210 (21.6%)           | 118 (24.9%)       |

Data expressed as mean ± standard deviation, median (interquartile range) or percentage.

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.
and insulin vs. those non-users, higher HbA1c and albumin levels were associated with higher sK. The association of sK with rapid renal progression and ESRD was U shape. Hypokalemia defined as <4 mEq/L and hyperkalemia as >5 mEq/L in our cohort were significantly associated with greater risk of ESRD.

Our results found hypokalemia to be a significant indicator of renal progression in CKD evidenced by 82% increased risk of reaching ESRD, rapid annual decline in eGFR and increase of proteinuria in CKD population. Our results are in accordance with a study of 1227 males with CKD by Kovesdy et al. They found that a sK = 3.6–5.5 mEq/L was associated with more severe progression (−0.23 ml/min/1.73 m²/yr, p = 0.002) compared to sK = 3.6–5.5 mEq/L [5]. On the contrary, Saran et al. reported that the association between hypokalemia (<4 mEq/L) and ESRD disappeared after adjustment for serum albumin. In our studies, we proposed that insufficient anti-hypertensive medication, increased diuretic use, insufficient RAS inhibition and malnutrition associated with hypokalemia could be related with worse outcomes.

We propose the following as plausible mechanisms: First, less use of anti-hypertensive mediation despite similar BP and greater diuretic use were associated with hypokalemia (Fig. 2B, and Table 3). Diuretics are often used in patients with heart and/or renal disease with volume overload. However, chronic diuretic use has been reported to be associated with higher long-term mortality and hospitalization for HF [18]. Our study (Table 4) as well as clinical studies and animal models have suggested a correlation between diuretic use and progression of renal disease [19]. Thiazides have been proposed to associate with renal injury via the induction of hypokalemia, metabolic abnormalities, and volume depletion and to lead to additional focal glomerular damage not observed in states of equivalent hypokalemia in the absence of diuretics [20].

Second, inadequate RAS inhibition related to either insufficient RAS blockade or resistance to RAS inhibitors may be related to hypokalemia. Insufficient RAS blockage was suggested by a greater extent of proteinuria and less use of ACEI/ARB in the hypokalemic population (Fig. 2C). There is well-established evidence that RAS inhibitors (ACEI or ARB) have beneficial effects on renal outcomes in both diabetic kidney disease and non-diabetic patients with proteinuria [21,22]. However, in the subgroup of ARB use in our cohort, hypokalemia was still associated with increased risk of ESRD. Previous studies had shown that ACE insertion/deletion (I/D) polymorphism contributed to the variability in ACEI treatment response and sodium-potassium balance [23–25]. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) reported the associations of mortality with new-onset hypokalemia (<3.5 mEq/L) and hyperkalemia (>5.4 mEq/L) determined at year-1 of treatment with chlorthalidone, lisinopril or amiodipine [26]. The risk of mortality among participants who developed hypokalemia by year 1 in the Lisinopril group was the highest (HR 3.925; CI: 2.26–6.44; P<0.001) than in either of the other 2 groups. From our result and previous reports, hypokalemia might be related to poor response to RAS blockade.

Third, hypoalbuminemia and lower BMI were associated with hypokalemia (Fig. 2A, Table 3). Hypoalbuminemia, as a marker of both nutritional and inflammatory status was associated with an increased rate of mortality in the population with renal disease [27–29]. Hypokalemia might also be a surrogate marker of malnutrition and correlated with hypoalbuminemia in both peritoneal and hemodialysis patients [30–32]. Both hypoalbumin-
Hypokalemia and hypokalemia remained significant predictors of worse renal outcomes when included simultaneously in the Cox regression model (Table 4). These findings may point out that hypokalemia is an independent risk factor for CKD progression and indicates additional prognostic importance of hypoalbuminemia.

Significant correlations between hypokalemia and alkalosis and hypertension respectively were observed (Table 3). Hypokalemia related augmented ammoniagenesis and subsequent renal injury has been documented [33]. Hypokalemia was also reported to stimulate renin and angiotensin II despite direct suppression of aldosterone synthesis leading to salt-sensitive hypertension, intrarenal vasoconstriction and ischemia [34–37]. Other mechanisms mediating renal injury in hypokalemia such as increased inflammatory mediators, oxidative stress [38] and impaired angiogenesis [39] have been reported. Human and animal pathologic studies also demonstrated that prolonged hypokalemia was accompanied by development of multiple renal medullary cysts, tubular degeneration, marked interstitial fibrosis and intense macrophage infiltration eventually leading to the impairment of renal function [6,40].

Hyperkalemia, beginning with serum values greater than >5 mEq/L in our cohort was associated with higher risk of ESRD. Recent post-hoc analysis of the RENAAL trial of Type 2 diabetes mellitus, by De Zeeuw et al. reported that increased sK $\geq$ 5 mEq/L after treatment with Losartan was associated with increased risk of ESRD. One potential mechanism could be the vicious cycle of increasing aldosterone levels in response to sustained hyperkalemia [41]. Aldosterone has been proposed to cause renal progression through both hemodynamic effects and direct cellular actions as it promotes endothelial dysfunction, facilitates thrombosis, reduces vascular compliance and causes myocardial and vascular fibrosis [42,43].

Our study has limitations to be considered. As an observational cohort, our ability to elucidate the definite causal links was limited. The variation of sK levels affected by nutritional status or medication use during the follow-up period could confound the results. However, the average sK level is a more precise description of baseline status than the single measurement mostly used in published studies. Even with markers of nutritional status such as serum albumin and BMI, lack of records of dietary intake might still confound the findings. Only a small group of patients in the sK $<$3.5 group had rapid progression (26.2%) and incident ESRD (8.2%). These patients also presented heavier proteinuria at baseline. We attempted to account for the differences in baseline proteinuria in our adjusted models. However, residual confounding by factors related to the underlying kidney diseases in these patients might still remain. This also limits our ability to make...
generalizations about the relationships between hypokalemia and renal outcomes. Finally, the follow-up period of 2.7 years could be relatively short for the assessment of progression to ESRD, especially for our study participants with higher eGFR. However, other indicators of renal progression such as the eGFR slope and proteinuria were examined and all pointed to the associations between worse renal outcomes and hypo- and hyperkalemia.

In conclusion, both hypokalemia and hyperkalemia are associated with elevated risk of developing ESRD in a CKD population. Hypokalemia is related to increased use of diuretics, decreased use of RAS blockade and malnutrition, all of which may impose additive deleterious effects on renal outcomes. Clinical implication may be drawn from our study that sK should be routinely evaluated and special attention given for sK between 3.5–4 mEq/L, generally considered as low “normal”. However, further clinical trials are required to determine if interventions aimed at achieving optimal sK level will slow the progression towards ESRD.

Supporting Information

Figure S1  Restricted Cubic Spline Regression Model of the Non-linear Effect of BMI, HbA1c and Albumin on sK. A. Body Mass Index (BMI) below 16.4 and above 36.1 kg/m² were associated with higher sK. Tick marks on the x-axis indicate individual observations at corresponding levels of BMI. The solid line represents the log transformed predictive value of serum potassium (sK). Same annotations were used for Figure S1B and S1C. B. HbA1c below 6.69 and above 12.79% were associated with higher sK. C. Albumin below 3.68 and above 4.56 mg/dL were associated with higher sK.

Figure S2  Restricted Cubic Spline Regression Model of the Hazard Ratio of sK, BMI, MBP and CRP for End Stage Renal Disease. A. Serum potassium (sK) below 4.03 and above 5.11 mEq/L were associated with higher hazard. Tick marks on the x-axis indicate individual observations at corresponding levels of sK. The solid line represents the log transformed multivariable-adjusted hazard ratio of ESRD. Same annotations were used for Figure S2B, S2C and S2D. B. Body Mass Index (BMI) below 23.36 and between 29.68 and 39.49 kg/m² were associated with higher hazard for ESRD. C. Mean blood pressure (MBP) below 72.27 and between 101.16 and 127.66 mmHg were associated with higher hazard for ESRD. D. C-reactive protein (CRP) below 39.36 mg/L was associated with higher hazard for ESRD.

Table S1

Table S2

Table 4. Association of Categorical Potassium with ESRD and Rapid Renal Progression in Full-Adjusted Model.

| Risk factors | ESRD | p | Rapid renal progression* | OR (95% CI) | p |
|--------------|------|---|--------------------------|-------------|---|
| constant     | 2.71 |   |                          | 3.04        |   |
| Diabetes mellitus | 1.57 (1.19 to 2.08) | 0.001 | 1.30 (1.00 to 1.69) | 0.047 |
| eGFR ml/min/1.73 m² | 0.92 (0.90 to 0.93) | <0.001 | 1.02 (1.01 to 1.02) | <0.001 |
| Proteinuria by dipstick | - | 1 (reference) | 1 (reference) | |
| +            | 2.06 (1.26 to 3.35) | 0.004 | 1.44 (1.02 to 2.02) | 0.036 |
| ++          | 4.11 (2.61 to 6.47) | <0.001 | 2.86 (2.04 to 3.99) | <0.001 |
| ++++        | 7.50 (4.73 to 11.88) | <0.001 | 4.83 (3.34 to 6.95) | <0.001 |
| ARB user vs non-user | 0.88 (0.69 to 1.12) | 0.312 | 0.69 (0.55 to 0.89) | 0.004 |
| Diuretics user vs non-user | 1.44 (1.07 to 1.93) | 0.015 | 1.14 (0.85 to 1.53) | 0.386 |
| Potassium sK = 3.5 mEq/L | 1.82 (1.03 to 3.22) | 0.041 | 1.69 (1.06 to 2.70) | 0.027 |
| sK = 4.5 mEq/L | 1.23 (0.89 to 1.70) | 0.205 | 1.12 (0.82 to 1.55) | 0.470 |
| Body mass index (kg/m²) | 0.96 (0.94 to 0.99) | 0.016 | 0.97 (0.95 to 1.00) | 0.072 |
| MBP (mmHg) | 1.01 (1.00 to 1.02) | 0.019 | 1.01 (1.01 to 1.02) | 0.001 |
| Phosphorus (mg/dL) | 1.36 (1.20 to 1.54) | <0.001 | 1.21 (1.05 to 1.39) | 0.008 |
| HbA1c (%) | 1.09 (1.02 to 1.17) | 0.013 | 1.10 (1.03 to 1.18) | 0.004 |
| Hemoglobin (g/dL) | 0.85 (0.79 to 0.92) | <0.001 | 0.82 (0.77 to 0.88) | <0.001 |
| Albumin (g/dL) | 0.45 (0.36 to 0.57) | <0.001 | 0.61 (0.49 to 0.77) | <0.001 |

* eGFR slope less than −6.88 ml/min/1.73 m²/yr.

Values expressed as hazard ratio (95% confidence interval) [HR (95% CI)] and odds ratio (95% confidence interval) [OR (95% CI)].

Full-adjusted model included age, gender, DM, CVD, eGFR, Urine protein by dipstick, ACEI, ARB, diuretics, MBP, BMI, HbA1c, log-transformed cholesterol, log-transformed CRP, phosphate, hemoglobin and albumin. Variables with significance were presented.

doi:10.1371/journal.pone.0067140.t004
Author Contributions
Conceived and designed the experiments: CCH HHW. Analyzed the data: HHW CCH SJH. Wrote the paper: HHW CCH.

References
1. Giebisch G, Hebert SC, Wang WH (2003) New aspects of renal potassium transport. Pflugers Arch 446: 209–297.

2. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, et al. (2009) The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 169: 1136–1142.

3. Moranne O, Froissart M, Rosset J, Gauci G, Boffa JJ, et al. (2009) Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 20: 164–171.

4. Korgonskar S, Tiele A, Gillespie BW, Kier M, Eisele G, et al. (2010) Serum potassium and outcomes in CKD: insights from the RRJ-CKD cohort study. Clin J Am Soc Nephrol 5: 762–769.

5. Ahmed A, Husain A, Love TE, Gambassi G, Dell'Italia LJ, et al. (2006) Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 27: 1431–1439.

6. Menahem SA, Perry GJ, Dowling J, Thomson NM (1999) Hypokalaemia-inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. J Am Soc Nephrol 16 Suppl 1: S58–63.

7. Hayes J, Kalantar-Zadeh K, Lu Jl, Turban S, Anderson JE, et al. (2011) Association of Hypo- and Hyperkalemia with Disease Progression and Mortality in Males with Chronic Kidney Disease: The Role of Race. Nephron Clin Pract 120: 8–16.

8. Greenberg A (2000) Diuretic complications. Am J Med Sci 319: 10–24.

9. Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, et al. (2012) Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail 5: 253–260.

10. Acker CG, Johnson JP, Palevsky PM, Greenberg A (1988) Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med 138: 917–924.

11. Maddirala S, Khan A, Vincent A, Lau K (2008) Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis. Am J Med Sci 336: 330–335.

12. Suga S, Mazzali M, Ray PE, Kang DH, Johnson RJ (2002) Angiotensin II type 1 receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev: CD006257.

13. Brodsky CP, Regidor DL, Melotra R, Jing J, McAllister CJ, et al. (2007) Serum and dihydrate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol 2: 999–1007.

14. Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, et al. (2012) Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail 5: 1431–1439.

15. Weiner ID, Wingo CS (1997) Hypokalemia–consequences, causes, and correction. J Am Soc Nephrol 8: 1179–1188.

16. Weiner ID, Wingo CS (1997) Hypokalaemia–consequences, causes, and correction. J Am Soc Nephrol 8: 1179–1188.

17. Yee TW, Wild CJ (1996) Vector generalized linear and additive models, R package, version 0.9–0 (URL: http://CRAN.R-project.org/package = VGAM. Accessed 2013 April 27.)

18. Yee TW (2012) VGAM: Vector generalized linear and additive models. R package, version 0.9–0 (URL: http://CRAN.R-project.org/package = VGAM. Accessed 2013 April 27.)

19. Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, et al. (2005) C-reactive protein and albumin as predictors of morbidity and cardiovascular events in chronic kidney disease (CKD) 3–5 patients. Clin Nephrol 67: 352–357.

20. Reungjui S, Roncal CA, Sato W, Glushakova OY, Croker BP, et al. (2008) Do thiazides inducing subtle renal injury not observed in states of equivalent hypokalemia. Hypertension 53: 25–30.

21. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC (2006) Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev: CD006257.

22. Chircuca C, Remuzzi G, Ruggenenti P (2005) Angiotensin-converting enzyme inhibition and renal protection in non-diabetic patients: the data of the meta-analyses. J Am Soc Nephrol 16 Suppl 1: S58–63.

23. Bauden B (2000) Angiotensin I-converting enzyme gene polymorphism and drug response. Clin Chem Lab Med 38: 833–836.

24. Parving HH, de Zeeuw D, Cooper ME, Remuzzi G, Liu N, et al. (2008) ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol 19: 771–779.

25. Reungjui S, Bettiaglio P, Pinares F, Remuzzi G (2008) Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and non-diabetic nephropathies. Clin J Am Soc Nephrol 3: 1511–1525.

26. Alderman MH, Pillar LR, Ford CE, Prosfield JL, Oparil S, et al. (2012) Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 59: 926–933.

27. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, et al. (1996) Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 7: 728–736.

28. Taal MW, Brenner BM (2006) Predicting initiation and progression of chronic kidney disease: Developing renal risk scores. Kidney Int 70: 1694–1705.

29. Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, et al. (2005) C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 65: 766–772.

30. Efringer TP, Tarver-Carr-ME, Powe NR, Appel LJ, Goreel J, et al. (2003) Leukocytosis, hypoalbuminemia, and the risk for chronic kidney disease in US adults. Am J Kidney Dis 42: 256–263.

31. Kovesdy CP, Regidor DL, Melotra R, Jing J, McAllister CJ, et al. (2007) Serum and dihydrate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol 2: 999–1007.

32. Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, et al. (2012) Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail 5: 253–260.

33. Greenberg A (2000) Diuretic complications. Am J Med Sci 319: 10–24.

34. Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, et al. (2005) C-reactive protein and albumin as predictors of morbidity and cardiovascular events in chronic kidney disease (CKD) 3–5 patients. Clin Nephrol 67: 352–357.

35. Tolins JP, Hostetter MK, Hostetter TH (1987) Hypokalemic nephropathy in the rat. Role of ammonia in chronic tubular injury. J Clin Invest 79: 1417–1429.

36. Ray PE, Suga S, Liu XJ, Huang X, Johnson RJ (2001) Chronic potassium depletion induces renal injury, salt sensitivity, and hypertension in young rats. Kidney Int 59: 1830–1830.

37. Suga SI, Phillips MI, Ray PE, Raleigh JA, Vio CP, et al. (2001) Hypokalemia induces renal injury and alterations in vasoactive mediators that favor salt sensitivity. Am J Physiol Renal Physiol 281: F620–629.

38. Adroger HJ, Madias NE (2007) Sodium and potassium in the pathogenesis of hypertension. N Engl J Med 356: 1966–1978.

39. Reungjui S, Roncal CA, Sato W, Glushakova OY, Croker BP, et al. (2008) Hypokalemic nephropathy is associated with impaired angiogenesis. J Am Soc Nephrol 19: 253–260.

40. Novello M, Catena C, Nadalini E, Cohuss GI, Barroelli S, et al. (2007) Renal crises and hypokalemia in primary aldosteronism: results of long-term follow-up after treatment. J Hypertens 25: 1443–1450.

41. Miao Y, Dobre D, Heerspink HJ, Brenner BM, Cooper ME, et al. (2011) Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia 54: 44–50.

42. Struthers AD, MacDonald TM (2004) Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 61: 663–670.

43. Epstein M (2001) Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertens 19: 829–842.